Genmab — Marts 2018

[Bulder]

Der er efterhånden en laang kø af stoffer, der bare længes efter at blive kombineret med dara.

[Bulder]

Interessant: " the combination of SGN-CD48A with daratumumab produced durable complete remissions in all animals. In contrast, combination of SGN-CD48A with elotuzumab did not produce additional antitumor activity. "

[E_L]

it will become increasingly difficult to keep track of all; but i guess that really is a luxury-problem

[bibob]

Next is Dara combined with Heineken.

[Bulder]

Yes we'll have to wait for the studies to become clinical studies. That will make the overview easier. But really encouraging that there are so many pre-clinical opportunities.

[E_L]

"no hang-over the day after" - would gaurantee triple-block-buster lol

[E_L]

2122 / 7 - Induction of structural and functional effects of myeloma cells after daratumumab treatment http://www.abstractsonline.com/pp8/#!/4562/presentation/1807

[E_L]

1890 / 21 "These results suggest that treatment by inecalcitol may render 95% of AML patients sensitive to highly sensitive to anti-CD38 immunotherapy such as daratumumab." http://www.abstractsonline.com/pp8/#!/4562/presentation/6586

[E_L]

ok Bulder, i'll save that question for Q&A

[Sukkeralf]

CD47 var ellers et favorittarget for mig nogle år tilbage, men Trillium Pharmaceuticals TTI-622 har skuffet en del. Celgene roder også med CD47

[Bulder]

Men måske kan det hjælpe at kombinere TTI-622 med dara?: TTI-622 monotherapy demonstrated partial tumor growth inhibition. However, the therapeutic efficacy was further enhanced when TTI-622 was combined with daratumumab.

[Sukkeralf]

Ja det er ikke til at sige - det kan man håbe på

[peter12]

Lidt mere om AQR hvis man keder sig https://youtu.be/MrziV33RjNQ . Forhåbentlig skal han have revideret
sin strategi snart

[E_L]

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients .....
https://clinicaltrials.gov/show/NCT03464916

[Bulder]

Vi skal være opmærksomme på abstract 3812 http://www.abstractsonline.com/pp8/#!/4562/presentation/8683 , der omhandler et nyt cd38 mAb fra Tusk, som også viser gode takter i solide tumorer. Desuden er der jo isatuximab, som vi tidligere har talt om. Dara får næppe monopol på PD1/PD-L1 kombi fremover. Tusk ser ud til at ville sende sin cd38 mAb i fase 1 allerede i år. https://www.tusktherapeutics.com/

[Bulder]

Men dara har klart fordelen af af være foran. Vi får de første resultater til sommer. De andre skal først til at starte nu.

[GeorgeBest]

Har Tusk en partner, eller kører de det alene?

[Bulder]

Ser ud til, de kører det alene indtil videre. I denne artikel mener de at deres cd38 mAb er bedre end dara h
ttps://www.tusktherapeutics.com/single-post/2017/12/21/biocentury-article-cd38-hat-trick

[Bulder]

https://www.tusktherapeutics.com/single-post/2017/12/21/biocentury-article-cd38-hat-trick

[Solsen]

Når dara sc er på markedet bliver det svært at slå ud